Skip to main content

Table 4 Clinico-pathological features of prostate cancer patients treated by radical prostatectomy

From: The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation

TMA series

Test

Validation

Number of patients

250

1262

Mean age at diagnosis

61

61

Median follow-up (months)

113

120

 

N

%

N

%

Gleason score at RP

≤3 + 3

64

25.6

392

31.1

3 + 4

104

41.6

499

39.5

4 + 3

42

16.8

188

14.9

≥4 + 4

36

14.4

175

13.9

NA

4

1.6

8

0.6

pTNM

2

171

68.4

788

62.4

3

77

30.8

453

35.9

4

2

0.8

21

1.7

Margin status

Negative

156

62.4

837

66.3

Positive

91

36.4

418

33.1

NA

3

1.2

7

0.6

Biochemical relapse

No

173

69.2

828

65.6

Yes

77

30.8

434

34.4

Type of biochemical relapse

Rising PSA

54

21.6

264

20.9

Failed RP

16

6.4

85

6.7

Treatment

7

2.8

85

6.7

Bone metastasis

No

239

95.6

1208

95.7

Yes

11

4.4

54

4.3

Castrate resistant

No

237

94.8

1201

95.2

Yes

13

5.2

61

4.8

Mortality

PC specific

4

1.6

36

2.9

Other cause(s)

17

6.8

119

9.4

Overall

21

8.4

155

12.3

  1. TMA tissue microarray, RP radical prostatectomy, pTNM pathological staging, NA not available, Rising PSA serum level of prostate-specific antigen (PSA) of 0.2 ng/mL and rising, Failed RP PSA level after surgery > 0.2 ng/mL, PC prostate cancer